Type and location of mutation: Among the 94 imatinib resistant CML patients, 37 (39%) patients had mutations in the ABL kinase domain of the BCR/ABL gene. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.